What a dental implant is, in clinical terms
A dental implant is a medical-grade titanium root surgically placed in the jawbone to replace the root of a missing tooth. After placement, the bone integrates directly with the implant surface — a biological process called osseointegration — and the integrated implant supports a fixed crown, bridge, or full-arch prosthesis. The procedure is well established in clinical literature and is recommended by NHS guidance for patients with one or more missing teeth where the surrounding bone and soft tissue are healthy enough to host the implant.
Long-term clinical studies report implant survival above 97% at ten years and above 90% at twenty years, where the implant is placed by a trained implantologist and supported by regular professional maintenance. Survival is driven by three variables: the quality of the surgical placement, the design and material of the implant system itself, and the patient's long-term oral-hygiene and professional-review schedule. Lifestyle factors — particularly smoking and uncontrolled diabetes — measurably reduce survival probability and are reviewed individually during candidacy assessment.
Three implant pathways are clinically distinct. A single-tooth implant replaces one missing unit. A multi-unit implant-supported bridge replaces two or more adjacent missing units, with the bridge supported by two or more strategically placed implants rather than one implant per tooth. Full-arch rehabilitation — the All-on-4 and All-on-6 protocols — replaces an entire arch of teeth on four or six implants, with a fixed prosthesis screwed into the implants rather than removed nightly. Each pathway has a different planning footprint and a different review cadence, and the choice between them is a clinical decision driven by bone volume, occlusion, and the patient's prosthetic plan.
The difference between a UK private pathway and an ATDERA-coordinated pathway in Turkey
A UK private dental implant pathway is a referral relationship between the patient and a single private practice. The patient registers at the practice, sits an in-person consultation with the implantologist, undergoes any imaging the practice routes to its in-house or external CBCT provider, receives a quotation drafted by the practice, and proceeds to treatment with the same clinician. Continuity of care is intrinsic to the model: the placing clinician is the reviewing clinician at six weeks, three months, and the prosthesis-fitting visit.
An ATDERA-coordinated pathway is a different shape. ATDERA Global Limited is a UK-registered international healthcare coordination organisation (Companies House #17173428); it does not own a clinical chair and does not deliver treatment directly. The pathway begins with a remote case review against the patient's existing imaging and clinical history. A verified partner implantologist on the ATDERA Care Network reviews the case and confirms candidacy in writing. A customised written estimate is then issued with the clinician fee, the implant brand, the prosthesis material, the surgical complexity, and any adjunctive procedure listed as separate line items, before any travel plan is made.
Treatment is delivered at a JCI-affiliated partner facility in Turkey. The patient travels for the surgical visit and a return visit at three to six months for the final prosthesis. Between the two visits, structured remote review with the treating clinician is scheduled within 1st week, 6th week, and 3rd month, and the pathway file is shared with the patient's UK or home-country dentist on request so continuity of care is preserved between the two surgical contacts. The clinical responsibility is held by the verified partner implantologist throughout; ATDERA holds the coordination responsibility — scheduling, intake, written estimate, post-operative remote follow-up — as a separate, organisation-level role.
The two pathways converge on the clinical evidence base. They differ on cost composition, scheduling cadence, and the verified-clinician structure. Neither model is correct for every patient: some patients prefer the in-person continuity of a local private practice; others prefer the documented pathway and the cost composition that a coordinated international pathway makes available. The evaluation that decides which model fits is a clinical conversation, not a marketing decision.
Evaluation, diagnostics, and verified-clinician transparency
The evaluation step on an ATDERA pathway is the most important single point in the patient's journey. The remote case review is built around three documents: a current panoramic radiograph, a 3D CBCT (cone beam CT) scan, and a structured clinical and medical history. The CBCT scan is the diagnostic that decides whether the planned implant trajectory is feasible, whether the residual bone volume is sufficient, and whether any adjunctive procedure — most commonly bone grafting or sinus floor elevation — is required before implant placement.
Where the existing imaging is older than twelve months or insufficient for surgical planning, the partner facility schedules a fresh CBCT in-country before the surgical visit. The image is read by the verified partner implantologist, the surgical plan is documented, and the patient receives a written summary before the procedure begins. This step is not a sales conversation: the clinical decision and any contraindication are surfaced in writing, and the patient is supported in seeking a second opinion if the recommendation is not clearly aligned with the symptoms presented.
Verified-clinician transparency is a structural feature, not a marketing line. Every clinician listed on an ATDERA Care Network treatment page carries current written permission to be publicly named. Their full name, professional title, sub-specialty, and years of practice are surfaced openly, with the source documentation held in ATDERA's editorial registry. The clinical responsibility for each case is held by the verified clinician identified during the evaluation, and the same clinician is on file in the post-operative review schedule rather than a rotating roster.
Implant systems and clinical materials
Internationally certified implant systems used through the ATDERA Care Network include Straumann (Switzerland) and Nobel Biocare (Switzerland) alongside other manufacturers. Both systems carry decades of peer-reviewed clinical data, are recognised by the European Association for Osseointegration, and are routinely used in NHS and UK private surgical contexts. The choice between systems is a clinical decision: implant geometry, surface treatment, healing-protocol compatibility, and the prosthetic plan all enter the decision, and the decision is made at the case-review stage in conjunction with the named implantologist.
The discussion patients sometimes encounter elsewhere — implant systems framed as a `premium tier` upsell against an unspecified `standard tier` — is not how an evidence-based clinical conversation runs. Manufacturer-level framing is the appropriate register: each manufacturer publishes its own clinical data, its own implant register, and its own long-term review documentation. The patient's pathway file records the implant brand, system, surface treatment, and serial numbers in writing, regardless of which manufacturer is selected.
Prosthetic material — the visible crown, bridge, or full-arch prosthesis fitted to the implant — is a separate clinical decision. Zirconia and lithium disilicate (IPS e.max, Ivoclar Vivadent) are the two most common ceramic options for implant-supported restorations on the ATDERA Care Network. Zirconia is selected for posterior load-bearing units and for full-arch rehabilitations where occlusal strength is the dominant variable; lithium disilicate is selected for anterior aesthetic units where translucency and shade matching are more important. The selection is made by the prosthodontist on the case team in conjunction with the placing implantologist, and the rationale is recorded in the patient's pathway file before fabrication begins.
Cost composition — customised written estimate vs bundled headline figure
Expenditure ranges for dental implant treatment delivered through the ATDERA Care Network in Turkey are typically a fraction of UK private clinic equivalents for the same implant brand, prosthesis material, and clinician seniority. Headline figures and comparative-savings statements are not how ATDERA quotes treatment. Each estimate is case-specific, issued in writing after the remote case review, and built from named cost components rather than a bundled headline number. The financial picture is settled in writing before any travel plan is made.
The line items in an ATDERA customised written estimate are: the clinician fee (placement and prosthetic-fitting visits), the implant brand and system, the prosthesis material and laboratory work, the surgical complexity (single-stage versus immediate-loading versus staged with adjunctive procedures), and any adjunctive procedure such as bone grafting, sinus floor elevation, or extraction of a non-restorable adjacent tooth. Each is listed independently so the patient and the patient's home-country dentist can read each one in isolation. Travel logistics are referenced in a separate logistics summary and are never bundled into the clinical estimate.
UK private dental implant fees are surveyed annually by the British Dental Association (BDA Private Fee Survey) and published in summary form by major UK private dental chains. The relative cost composition between the two pathways is structural rather than promotional: the same implant brand and the same prosthesis material at a JCI-affiliated partner facility carry a measurably different cost composition from the equivalent at a UK private practice, driven by the underlying labour, facility, and laboratory inputs in each market. Patients who want to read the underlying provenance can consult the BDA fee survey alongside the case-specific written estimate the ATDERA pathway issues.
Recovery, osseointegration, and follow-up cadence
Immediate post-operative recovery follows a documented pattern. A soft diet is recommended for one to two weeks during initial soft-tissue healing. A chlorhexidine mouth rinse and prescribed analgesics are issued at the partner facility, and prophylactic antibiotics are prescribed where clinically indicated. Mild swelling and discomfort are expected during the first three to five days. Patients typically return to office work within two to three days for single-tooth cases and within five to seven days for full-arch cases.
The implant osseointegrates with the surrounding bone over three to six months. During this period, a temporary restoration may be worn where the implanted unit is in the visible smile zone. The osseointegration period is a biological constant that is not shortened by treatment compression: clinical compromises occur when the final prosthesis is loaded before integration is complete, which is why the ATDERA pathway separates the surgical visit and the final prosthesis fitting into two distinct travel dates rather than collapsing them into a single short visit.
Structured remote review with the treating clinician is scheduled within 1st week, 6th week, and 3rd month after surgery. The review is conducted by video and a structured clinical questionnaire, with photographs of the surgical site contributed by the patient. Where an in-person check is needed between scheduled reviews, the patient's home dentist is supported with the relevant clinical documentation from ATDERA's pathway file on request. After the final prosthesis is fitted, the long-term review schedule continues at month 6, year 1, and annually thereafter, with implant stability, occlusion, and oral-hygiene reviewed as a coordinated pathway through the partner clinician on file.
Implant Passport documentation
Each implant placement on the ATDERA Care Network is recorded on the manufacturer's implant passport — the recognised industry-standard documentation that travels with the patient. Straumann's Patient Pass and Nobel Biocare's Implant Passport are the two most widely used examples; equivalent documentation is provided for other internationally certified implant systems used through the network. The passport captures the implant brand and system, the abutment configuration, the surgical date, the treating clinician, and the implant serial numbers, and it is provided to the patient before they return home.
The implant passport matters because the patient's clinical relationship with the implant is lifelong. Any future review anywhere in the world — whether routine maintenance with the patient's UK dentist, replacement of a prosthetic component a decade after placement, or unrelated dental or surgical work where the implant register is clinically relevant — has the technical record of the implant in front of it. Without that record, a clinician reviewing the implant in five or ten years has to reconstruct the surgical and prosthetic specification from intra-oral imaging, which is slower, more error-prone, and occasionally impossible.
ATDERA also retains a duplicate of the passport in the patient's pathway file, accessed through the care coordinator on request. This is a coordination-level safety net rather than a clinical-record substitute: the patient's primary record is the original passport issued at the partner facility, and the patient's UK or home-country dentist holds the relationship of record for routine maintenance once the patient has returned home.
How to begin an evaluation with ATDERA
An evaluation begins with the pre-consultation enquiry. The intake collects the patient's clinical history, current imaging where available, and the procedure interest. A verified partner implantologist on the ATDERA Care Network reviews the case and confirms candidacy in writing, typically within one working day. The remote review is the gating step: where the imaging or clinical history makes a confident recommendation difficult, the partner facility may request a fresh CBCT or a focused clinical photograph before the written estimate is finalised.
Once the case is reviewed, a customised written estimate is issued with the clinician fee, the implant brand, the prosthesis material, the surgical complexity, and any adjunctive procedure listed as separate line items. The patient reads the estimate in their own time, alongside their UK or home-country dentist if helpful, and decides whether to proceed. There is no commitment to travel until the pathway is confirmed in writing, and no clinical scheduling begins before the patient confirms in writing that they want to proceed.
Patients who decide not to travel after the evaluation are not pursued. The evaluation step is a clinical conversation; the decision to travel is a patient decision. Where the conclusion of the review is that an in-country UK private pathway or a continuation of the patient's NHS pathway is the better fit for the case, that conclusion is stated in writing and the pathway file is closed. The structure of the ATDERA pathway is built so the patient walks into the surgical visit having already read, understood, and signed the clinical and financial picture in advance.